-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse NasdaqISIN US09609G1004-
bluebird bioBörse Börse FrankfurtEURSymbol BLE
-
bluebird bioBörse Börse MünchenEURSymbol BLE
-
bluebird bioBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol BLE
-
bluebird bioBörse Gettex System der Börse MünchenEURSymbol BLE
-
bluebird bioBörse NasdaqISIN US09609G1004 WKN: A1W025Symbol BLUE
-
ISIN US09609G1004 WKN: A1W025USDSymbol BLUE
-
Symbol BLE
-
MXN
-
USD
-
ISIN US09609G1004
WKN A1W025
Symbol BLUE
Börse
Nasdaq Zeitzone: America/New_York
Firmenname
Bluebird bio Inc
Marktkapitalisierung
14.538.463.000 (+- 98%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
321.926.000 oder 28.755.000.000
Mitarbeiter
747 (+- 57%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
1.171 oder 323 Mitarbeiter
EBITDA -133.210.000
PEGRatio 0.32
Buchwert 2.715
bluebird bio outperformed den DAX um +11 % vom 06.05.2014 bis 17.06.2021
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 30,41 USD +1,67%
Portrait der bluebird bio Aktie
Das Unternehmen Bluebird bio Inc aus USA beschäftigt 747 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie tätig.
Die bluebird bio Aktie konnte seit dem 06.05.2014 eine Rendite von 75% erwirtschaften.
Das Unternehmen Bluebird bio Inc ist in ungefähr 10 ETFs enthalten und somit eine nicht sonderlich bekannte oder beliebte Aktie. Der Spitzenreiter Global X Genomics & Biotechnology ETF gewichtet bluebird bio mit 1,89% im ETF.
Entdecke die 6 ETFs in denen Bluebird bio Inc am höchsten gewichtet ist Insgesamt in 10 ETFs enthalten
Dir gefallen die Informationen zu bluebird bio?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu bluebird bio?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu bluebird bio?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu bluebird bio?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
35 News & Informationen zur bluebird bio Aktie
Will Moderna’s Interest Boost Gene Editing Stocks?
Our indicative theme of Gene Editing stocks has returned about 11% year-to-date, compared to the S&P 500 which is up by about 19% over the same period. However, the gains have overwhelmingly come from a single stock, Intellia Therapeutics, which is up by about 3x year-to-date, after the company…
BLUEBIRD BIO INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. – BLUE
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into bluebird bio, Inc…. | August 14, 2021
bluebird bio – A Speculative Trade (NASDAQ:BLUE)
BLUE is trading near its cash/cash equivalent per share, pointing that the ticker is oversold. The company remains a speculative trade.
bluebird bio Inc. Stock Quote (U.S.: Nasdaq)
BLUE | Complete bluebird bio Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Inhibrx Reports Second Quarter 2021 Financial Results
/PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the…
Why Bluebird Bio's Stock Is Trading Lower Today
Bluebird Bio Inc (NASDAQ:BLUE) is trading lower Monday after the company reported worse-than-expected second-quarter financial results and an…
Bluebird Bio, Inc. (BLUE) CEO Nick Leschly on Q2 2021 Results – Earnings Call Transcript
Bluebird Bio, Inc. (NASDAQ:BLUE) Q2 2021 Earnings Conference Call August 09, 2021, 08:00 AM ET Company Participants Nick Leschly – Chief Executive Officer Elizabeth Pingpank – Direct…
bluebird bio, Inc. 2021 Q2 – Results – Earnings Call Presentation (NASDAQ:BLUE)
The following slide deck was published by bluebird bio, Inc.
Bluebird's stock falls 21% as it says it will focus on U.S. market for gene therapies, citing 'European payers'
Shares of Bluebird Bio Inc. undefined were down 21.6% in premarket trading on Monday after the company announced several setbacks to its business as part of…
Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates
Bluebird (BLUE) delivered earnings and revenue surprises of -9.82% and -55.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
bluebird bio Reports Second Quarter Financial Results and Provides Operational Update
– On track to complete planned business separation in 4Q 2021; each company launching with approximately 24 months of runway following separation –
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnin…
bluebird bio : Announces Q2 Earnings Call and Upcoming Investor Events
bluebird bio, Inc. today announced that the Company will report financial results for the second quarter ended June 30, 2021 on Monday, August 9, 2021 and host a conference call to discuss the… | August 5, 2021
Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?
After receiving yet another treatment approval from regulators, Bluebird Bio looks like a bargain.
Bluebird bio : Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched
bluebird bio Receives EC Approval for SKYSONA™ Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy Without Matched Sibling Donor
… | July 21, 2021
Hedge Funds Aren’t Crazy About USANA Health Sciences, Inc. (USNA) Anymore
In this article we will take a look at whether hedge funds think USANA Health Sciences, Inc. (NYSE:USNA) is a good investment right now. We check hedge…
Is The RealReal, Inc. (REAL) Going to Burn These Hedge Funds?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data….
Hedge Funds Are Souring On bluebird bio Inc (BLUE)
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact,…
bluebird bio Inc (BLUE): Price Down $-0.62 (-2.08)% Over Past Day, Down $-0.37 (-1.26)% Over Past Hour
Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon?
Neither healthcare stock has performed well so far this year.
VBL Therapeutics Appoints Alison Finger And Michael Rice To Its Board Of Directors
TEL AVIV, Israel, July 08, 2021 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) today announced the appointments of Alison Finger and Michael Rice to its
Surface Oncology Appoints Denice Torres To Board Of Directors
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation
Surface Oncology Appoints Denice Torres to Board of Directors
Brings 25 years of strategic leadership experience across healthcare…
2 Reasons to Buy Intellia — and 1 Big Reason Why I Won't
After the clinical-stage biotech publicized promising data for its gene-editing treatment of a rare and fatal disease, its stock skyrocketed.
Gene Editing Stocks Are Worth A Look After Intellia’s Big Breakthrough
Intellia Therapeutics – a gene-editing company co-founded by CRISPR pioneer and Nobel prize winner Jennifer Doudna – indicated that NTLA-2001, its experimental treatment for transthyretin amyloidosis provided very promising results in an early state trial. Although the study was small, including…
Should I Buy Chesapeake Utilities Corporation (CPK)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data….
Global Gene Therapy Market To Reach $2.7 Billion By 2026
SAN FRANCISCO, June 29, 2021 /PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today
Will This 2020 Biotech IPO Crush the Market This Year?
Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021.
Top Stocks To Buy This Week? 4 Health Care Stocks To Watch
Check out these trending names in the health care industry.
TUESDAY DEADLINE ALERT: ROSEN, A TOP RANKED FIRM, Encourages bluebird bio, Inc. Investors With Losses Over $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action – BLUE
NEW YORK, April 11, 2021 /PRNewswire/ —
WHY: Rosen Law Firm, a global investor… | April 11, 2021
IRW-News: Medigene AG: Medigene AG: AACR-Daten zeigen Eigenschaften von Medigenes führendem TCR-Kandidaten gegen solide Tumore
IRW-News: Medigene AG: Medigene AG: AACR-Daten zeigen Eigenschaften von Medigenes führendem TCR-Kandidaten gegen solide Tumore | Nachricht | finanzen.net
Medigene : AACR data show characteristics of Medigene's lead TCR candidate against solid tumors
Planegg/Martinsried – Medigene AG , a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, today presents promising pre-clinical data on its lead… | April 10, 2021
Medigene : Identification of ten novel tumor-specific antigens immunogenic for T cells
Planegg/Martinsried and Montr? – 10 April 2021. Medigene AG , a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, today presents the… | April 10, 2021
Bristol-Myers Freeing Up Cash for Additional Acquisitions
Bristol-Myers Freeing Up Cash for Additional Acquisitions, Stocks: BMY,BLUE, release date:Jan 14, 2021
IRW-News: Medigene AG: Medigene AG: Medigene erweitert den Patentschutz fr ihre Technologien in Schlsselmrkten wie den USA und Europa
IRW-News: Medigene AG: Medigene AG: Medigene erweitert den Patentschutz fr ihre Technologien in Schlsselmrkten wie den USA und Europa | Nachricht | finanzen.net